These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 20074459

  • 1. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
    Caldarola G, De Simone C, Carbone A, Tulli A, Amerio P, Feliciani C.
    Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
    [Abstract] [Full Text] [Related]

  • 2. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept.
    Lizzul PF, Aphale A, Malaviya R, Sun Y, Masud S, Dombrovskiy V, Gottlieb AB.
    J Invest Dermatol; 2005 Jun; 124(6):1275-83. PubMed ID: 15955104
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Reduction of different inflammatory cell types of the innate immune system in psoriatic skin during etanercept treatment.
    de Groot M, Teunissen MB, Picavet DI, de Rie MA, Bos JD.
    Exp Dermatol; 2010 Aug; 19(8):754-6. PubMed ID: 20482616
    [Abstract] [Full Text] [Related]

  • 5. Etanercept does not have an apoptosis-inducing effect on psoriatic keratinocytes.
    Tatlican S, Arikok A, Gulbahar O, Eren C, Cevirgen B, Eskioglu F.
    J Dermatolog Treat; 2010 Sep; 21(5):306-10. PubMed ID: 19878038
    [Abstract] [Full Text] [Related]

  • 6. Etanercept.
    Ducharme E, Weinberg JM.
    Expert Opin Biol Ther; 2008 Apr; 8(4):491-502. PubMed ID: 18352852
    [Abstract] [Full Text] [Related]

  • 7. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
    Campanati A, Goteri G, Simonetti O, Ganzetti G, Giuliodori K, Giuliano A, Sabato S, Stramazzotti D, Gulini E, Dusi D, De Blasio S, Fabris G, Offidani A.
    Int J Immunopathol Pharmacol; 2009 Apr; 22(2):371-7. PubMed ID: 19505391
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
    Zaba LC, Suárez-Fariñas M, Fuentes-Duculan J, Nograles KE, Guttman-Yassky E, Cardinale I, Lowes MA, Krueger JG.
    J Allergy Clin Immunol; 2009 Nov; 124(5):1022-10.e1-395. PubMed ID: 19895991
    [Abstract] [Full Text] [Related]

  • 10. Etanercept for psoriasis: two case reports.
    Fidalgo A, Baptista J, Rocha Páris F, Caldas Lopes L, Ferreira A.
    Int J Clin Pharmacol Res; 2005 Nov; 25(4):159-63. PubMed ID: 16402631
    [Abstract] [Full Text] [Related]

  • 11. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24.
    Wang F, Smith N, Maier L, Xia W, Hammerberg C, Chubb H, Chen C, Riblett M, Johnston A, Gudjonsson JE, Helfrich Y, Kang S, Fisher GJ, Voorhees JJ.
    Br J Dermatol; 2012 Jul; 167(1):92-102. PubMed ID: 22458549
    [Abstract] [Full Text] [Related]

  • 12. Clinical markers predictive of primary inefficacy: a "real life" retrospective study in psoriatic patients treated with etanercept.
    Giunta A, Babino G, Manetta S, Mazzotta A, Chimenti S, Esposito M.
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S27-30. PubMed ID: 25381970
    [Abstract] [Full Text] [Related]

  • 13. Etanercept, a TNF antagonist for treatment for psoriatic arthritis and psoriasis.
    Mease PJ.
    Skin Therapy Lett; 2003 Jan; 8(1):1-4. PubMed ID: 12728284
    [Abstract] [Full Text] [Related]

  • 14. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation.
    Johnston A, Fritz Y, Dawes SM, Diaconu D, Al-Attar PM, Guzman AM, Chen CS, Fu W, Gudjonsson JE, McCormick TS, Ward NL.
    J Immunol; 2013 Mar 01; 190(5):2252-62. PubMed ID: 23359500
    [Abstract] [Full Text] [Related]

  • 15. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
    Gottlieb AB, Chamian F, Masud S, Cardinale I, Abello MV, Lowes MA, Chen F, Magliocco M, Krueger JG.
    J Immunol; 2005 Aug 15; 175(4):2721-9. PubMed ID: 16081850
    [Abstract] [Full Text] [Related]

  • 16. Etanercept downregulates the Th17 pathway and decreases the IL-17+/IL-10+ cell ratio in patients with psoriasis vulgaris.
    Antiga E, Volpi W, Cardilicchia E, Maggi L, Filì L, Manuelli C, Parronchi P, Fabbri P, Caproni M.
    J Clin Immunol; 2012 Dec 15; 32(6):1221-32. PubMed ID: 22699761
    [Abstract] [Full Text] [Related]

  • 17. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy.
    Hamilton TK.
    J Drugs Dermatol; 2008 Nov 15; 7(11):1089-93. PubMed ID: 19110745
    [Abstract] [Full Text] [Related]

  • 18. Early tissue responses in psoriasis to the antitumour necrosis factor-α biologic etanercept suggest reduced interleukin-17 receptor expression and signalling.
    Johnston A, Guzman AM, Swindell WR, Wang F, Kang S, Gudjonsson JE.
    Br J Dermatol; 2014 Jul 15; 171(1):97-107. PubMed ID: 24601997
    [Abstract] [Full Text] [Related]

  • 19. Expression of antimicrobial peptides and proteins in etanercept-treated psoriasis patients.
    Gambichler T, Kobus S, Kobus A, Tigges C, Scola N, Altmeyer P, Kreuter A, Bechara FG, Skrygan M.
    Regul Pept; 2011 Apr 11; 167(2-3):163-6. PubMed ID: 21324346
    [Abstract] [Full Text] [Related]

  • 20. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
    Martínez-Abundis E, Reynoso-von Drateln C, Hernández-Salazar E, González-Ortiz M.
    Arch Dermatol Res; 2007 Nov 11; 299(9):461-5. PubMed ID: 17726611
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.